1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSI
TriSalus Life Sciences, Inc.US flagNASDAQ Global Market
4.30
USD
+0.53
- -
162.82MMarket Cap

Total Valuation

TriSalus Life Sciences, Inc. carries a market capitalization of 162.82M, placing it among publicly traded companies globally. Its enterprise value stands at 152.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap162.82M
Enterprise Value152.28M

Share Statistics

TriSalus Life Sciences, Inc. currently has 61.41M shares outstanding.

Shares Outstanding61.41M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.88, and the price-to-book ratio stands at -0.53.

PE RatioN/A
PS Ratio3.88
PB Ratio-0.53
P/TBV Ratio13.61
P/FCF Ratio-8.89
P/OCF Ratio-8.72

Enterprise Valuation

EV / Sales3.39
EV / EBITDAN/A
EV / EBITN/A
EV / FCF14.00

Financial Position

TriSalus Life Sciences, Inc. maintains a current ratio of 5.78, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 269.28, indicating elevated leverage, while an interest coverage ratio of -4.75 demonstrates limited ability to service its debt obligations.

Current Ratio5.78
Quick Ratio5.24
Debt / Equity269.28
Debt / EBITDA-1.26
Interest Coverage-4.75

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-54.84
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)-1.97
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.69

Taxes

Over the trailing twelve months, TriSalus Life Sciences, Inc. has paid 6,000.00 in income taxes, reflecting an effective tax rate of 0.26.

Income Tax6,000.00
Effective Tax Rate0.26

Stock Price Statistics

TriSalus Life Sciences, Inc.'s stock has declined approximately -22.05082% over the past 52 weeks. The 50-day moving average sits at 3.90, while the 200-day moving average is 4.87.

Beta (5Y)N/A
52-Week Price Change-22.05082%
50-Day Moving Average3.90
200-Day Moving Average4.87
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, TriSalus Life Sciences, Inc. generated 44.88M in revenue and converted that into -27.31M in net income, yielding earnings per share of -0.62. EBITDA reached -27.44M, while operating income came in at -28.03M.

Revenue44.88M
Gross Profit38.18M
Operating Income-28.03M
Pretax Income-27.31M
Net Income-27.31M
EBITDA-27.44M
EBIT-28.03M
Earnings Per Share (EPS)-0.62

Balance Sheet

TriSalus Life Sciences, Inc. holds 56.55M in cash and equivalents against 34.49M in total debt, resulting in a net debt position of -23.47M. Total book value stands at -329.04M, with working capital of 56.35M providing operational flexibility.

Cash & Cash Equivalents56.55M
Total Debt34.49M
Net Debt-23.47M
Equity (Book Value)-329.04M
Book Value Per Share-7.55
Working Capital56.35M

Cash Flow

TriSalus Life Sciences, Inc. produced -19.99M in operating cash flow over the past twelve months. After subtracting -305,000.00 in capital expenditures, free cash flow totaled -20.30M - equivalent to -0.47 per share.

Operating Cash Flow-19.99M
Capital Expenditures-305,000.00
Free Cash Flow-20.30M
FCF Per Share-0.47

Margins

TriSalus Life Sciences, Inc. operates with a gross margin of 85.07, reflecting its pricing power and cost economics. The operating margin of -62.45 and net profit margin of -60.85 provide insight into operational efficiency.

Gross Margin85.07
Operating Margin-62.45
Pretax Margin-60.84
Profit Margin-60.85
EBITDA Margin-61.13

Dividends & Yields

The company's payout ratio of 2.55 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio2.55
Shareholder Yield-36.40
FCF Yield-11.24

Scores

TriSalus Life Sciences, Inc. posts an Altman Z-Score of -4.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-4.41